| 51.39 Real-Time Quote | -0.10 / -0.19%Today’s Change | 40.86 Today|||52-Week Range 53.45 | +8.72% Year-to-Date |
| Priority Review for AZN/BMY Drug - Analyst Blog Jun 06 / Zacks.com | AstraZeneca Presents Olaparib Data - Analyst Blog Jun 03 / Zacks.com |
| Encouraging Data on Isis Candidate - Analyst Blog Jun 06 / Zacks.com | NICE News for BMY/AstraZeneca - Analyst Blog May 30 / Zacks.com |
| AstraZeneca to Return Fostamatinib Rights - Analyst Blog Jun 05 / Zacks.com | AstraZeneca to Buy Omthera Pharma - Analyst Blog May 29 / Zacks.com |
| How AstraZeneca Measures Up as a GARP Investment Jun 05 / MotleyFool.com | AZN Updates on Pulmicort Respules - Analyst Blog May 28 / Zacks.com |